Compare · CNC vs FLGT
CNC vs FLGT
Side-by-side comparison of Centene Corporation (CNC) and Fulgent Genetics Inc. (FLGT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNC and FLGT operate in Medical Specialities (Health Care), so they compete in similar markets.
- CNC is the larger of the two at $34.83B, about 59.3x FLGT ($587.2M).
- CNC has been more active in the news (14 items in the past 4 weeks vs 1 for FLGT).
- CNC has more recent analyst coverage (25 ratings vs 9 for FLGT).
- Company
- Centene Corporation
- Fulgent Genetics Inc.
- Price
- -
- -
- Market cap
- $34.83B
- $587.2M
- 1M return
- +3.03%
- -
- 1Y return
- +96.07%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 14
- 1
- Recent ratings
- 25
- 9
Centene Corporation
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Fulgent Genetics Inc.
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves insurance, hospitals, and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. Fulgent Genetics has collaboration with PWNHealth to provide at-home COVID-19 test capabilities. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Latest CNC
- Centene Corporation Demonstrates Commitment to CHOICE Arrangements through Benefit Programs in Indiana, Ohio and Oklahoma
- SEC Form 4 filed by Centene Corporation
- PA Health & Wellness Earns National Recognition Among Top Medicaid Health Plans for Second Consecutive Year
- Centene to Launch Nationwide Gold Card Program for Qualifying Providers
- SEC Form 8-K filed by Centene Corporation
- Ambetter Health Solutions and Marathon Health Expand Access to Primary Care for Members in Indiana and Missouri
- Wellcare Unveils 2027 Medicare Offerings Focused on Affordability and Integrated Care
- Director Tyler Lauren M was granted 482 shares, increasing direct ownership by 15% to 3,698 units (SEC Form 4)
- Director Tanji Kenneth was granted 603 shares, increasing direct ownership by 5% to 13,093 units (SEC Form 4)
- Director Samuels Theodore R. Ii was granted 583 shares, increasing direct ownership by 2% to 25,796 units (SEC Form 4)
Latest FLGT
- Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026
- CFO and Treasurer Kim Paul covered exercise/tax liability with 2,087 shares, decreasing direct ownership by 0.58% to 356,543 units (SEC Form 4) (withholding tax)
- Chief Executive Officer Hsieh Ming covered exercise/tax liability with 4,392 shares, decreasing direct ownership by 0.49% to 885,952 units (SEC Form 4) to satisfy tax liability
- Chief Scientific Officer Gao Hanlin sold $32,885 worth of shares (1,673 units at $19.66), decreasing direct ownership by 0.17% to 986,117 units (SEC Form 4) (withholding tax)
- President and COO Xie Jian sold $41,809 worth of shares (2,127 units at $19.66), decreasing direct ownership by 0.59% to 359,924 units (SEC Form 4) to satisfy withholding obligation
- Chief Executive Officer Hsieh Ming covered exercise/tax liability with 2,949 shares, decreasing direct ownership by 0.33% to 890,344 units (SEC Form 4) (withholding obligation)
- CFO and Treasurer Kim Paul covered exercise/tax liability with 1,168 shares, decreasing direct ownership by 0.32% to 358,630 units (SEC Form 4) to satisfy tax liability
- President and COO Xie Jian sold $23,747 worth of shares (1,193 units at $19.91), decreasing direct ownership by 0.33% to 362,051 units (SEC Form 4) to satisfy withholding tax
- Chief Scientific Officer Gao Hanlin sold $18,691 worth of shares (939 units at $19.91), decreasing direct ownership by 0.09% to 987,790 units (SEC Form 4) to satisfy withholding obligation
- SEC Form 10-Q filed by Fulgent Genetics Inc.